Who is sponsoring NCT04511000?

NCT04511000 is sponsored by Chong Kun Dang Pharmaceutical.

What drugs are being tested in NCT04511000?

Interventions in NCT04511000: Lipilou®(generic atorvastatin drug) 20 mg, Lipilou®(generic atorvastatin drug) 10 mg.

What condition does NCT04511000 study?

NCT04511000 studies Hypercholesterolemia.

Is NCT04511000 still recruiting?

NCT04511000 is currently completed. Last updated 12 August 2020.

Last reviewed 2020-08-12 · How we verify

NCT04511000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg

Completed Phase 4 Last updated 12 August 2020

What this trial tests

Phase 4 trial testing Lipilou®(generic atorvastatin drug) 20 mg in Hypercholesterolemia in 250 participants. Completed in 20 May 2019.

Timeline

11 October 2017

Primary endpoint
20 May 2019

20 May 2019

Quick facts

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	250
Start date	11 October 2017
Primary completion	20 May 2019
Estimated completion	20 May 2019
Sites	10 locations across South Korea

Drugs / interventions tested

Lipilou®(generic atorvastatin drug) 20 mg — full drug profile →
Lipilou®(generic atorvastatin drug) 10 mg — full drug profile →

Conditions studied

Hypercholesterolemia — all drugs for Hypercholesterolemia →

Sponsor

Chong Kun Dang Pharmaceutical — full company profile →

Who can join

19 and older, any sex, with Hypercholesterolemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to compare the mean percent change of LDL-C between Lipilou® 10mg and 20mg group after 12 weeks of treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.
Kim JB, Song WH, Park JS, Youn TJ, et al · · 2021 · cited 5× · PMID 33481866 · DOI 10.1371/journal.pone.0245481

Verify or expand the search:

Other recruiting trials for Hypercholesterolemia

Currently open trials in the same condition.

NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07295327 — Effect of Two Food Supplements on Lipid Profile in Patients With Mild Hypercholesterolemia · NA · recruiting
NCT06568601 — Pharmacogenomic Informed Statin Prescribing · NA · recruiting
NCT06423365 — A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication. · NA · active not recruiting

Other Chong Kun Dang Pharmaceutical trials

Trials by the same sponsor.

NCT07404735 — A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 · Phase 1 · not yet recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
NCT07258745 — Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-appro · Phase 1 · recruiting
NCT07304726 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers · Phase 1 · completed
NCT07304700 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04511000 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chong Kun Dang Pharmaceutical
Last refreshed: 12 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04511000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing